Home  /  Regulatory Affairs  /  SFDA (Saudi Arabia)
Regulatory Affairs · Saudi Arabia

SFDA Submission Support (Saudi Arabia)

The Saudi Food and Drug Authority (SFDA), a WHO Maturity Level 4 regulator and a de facto reference authority across the region, oversees the largest pharmaceutical market in the Middle East. EvySaif prepares the dossiers, pricing documentation, and regulatory strategy for SFDA submissions, so your entry into the Saudi market is built correctly from the first filing.

SDR systemeCTD & SFDA Module 1Economic evaluationGCC pathway
SFDA · Route
EnrollmentDrug Establishments National Registry
DossiereCTD submitted through the SDR system
Validation and reviewAutomated checks, then assessment
RegistrationFive-year approval, with pricing set
The Pathway

Understanding the SFDA pathway

Registration runs through the Saudi Drug Registration (SDR) system, and begins with enrollment in the Drug Establishments National Registry. Dossiers are submitted in eCTD format on the CTD structure, and the SFDA's automated system validates Module 1 and eCTD compliance before any human review, so structural errors cause early rejection.

Pick the review route

The SFDA offers a verification pathway for products already approved by recognized reference authorities such as the FDA, EMA, and MHRA, and a full-review pathway for new chemical entities.

VerificationFull review

Build pricing into the file

Pricing is integral to registration. Applicants provide a price certificate and international reference prices, and since 1 July 2025 an Economic Evaluation Study is required for products undergoing pricing.

Price certificateReference pricesEconomic evaluation

Meet the local requirements

Arabic labelling is mandatory, a foreign company must appoint a Saudi Authorized Representative, and a qualified person for pharmacovigilance connects to the National Pharmacovigilance Center.

Arabic labellingSaudi ARQPPV

Register, then extend

Approval yields a five-year registration. Saudi Arabia also participates in the GCC centralised registration pathway, which can extend recognition across the six GCC states.

GCC pathway
At a Glance
AuthoritySFDA, WHO Maturity Level 4
SystemSaudi Drug Registration (SDR)
FormateCTD with SFDA Module 1
RoutesVerification or full review
PricingEconomic evaluation since July 2025
ValidityFive-year registration

Foreign companies: the SFDA requires a Saudi Authorized Representative to hold the registration and file. EvySaif prepares the dossier and strategy and works alongside that representative, not as it.

Deliverables

What we prepare

SDR eCTD dossiersCTD and eCTD dossiers with SFDA Module 1 compliance.

Pathway packagesVerification-pathway and full-review submission packages.

Pricing and economicsPricing dossier support and economic evaluation documentation.

Regulatory strategyPathway selection, reference-country planning, and GCC route assessment.

Query responses and PVResponses to SFDA requests for information, plus pharmacovigilance documentation.

Labelling contentArabic and English SmPC and PIL preparation.

Partnership

How EvySaif helps

We are your dossier writing and strategy partner for Saudi Arabia. We build the eCTD submission, prepare the pricing and economic evaluation content, and advise on the verification versus full-review decision and the GCC option. Because the SFDA requires a Saudi Authorized Representative to hold the registration and file, we work alongside yours, giving you a submission that is both well prepared and correctly routed.

Build the eCTD submission for the SDR system
Prepare the pricing and economic evaluation content
Advise on verification versus full review, and the GCC option
Work alongside your Saudi Authorized Representative

Why EvySaif

EvySaif is one of the best research and medical writing consultancies in India, and it shows in the quality of every deliverable. Saudi Arabia is a priority market for us, and our HEOR capability is a particular advantage here, since the economic evaluation now required for pricing is exactly the kind of cost-effectiveness work we build. Few writing partners can prepare both the dossier and the health economics behind it.

Questions

Frequently asked questions

The Saudi Drug Registration system is the SFDA's electronic platform for drug registration submissions, which begins with registration in the Drug Establishments National Registry.

Since 1 July 2025 the SFDA requires an Economic Evaluation Study for products undergoing pricing. EvySaif can prepare both the regulatory dossier and the economic evaluation.

Yes. A foreign company must appoint a Saudi Authorized Representative to hold the registration and file. We prepare the dossier and strategy and work alongside that representative.

Have a different question?

Tell us about your product, market, and timeline, and a clinician on our team will reply with specifics rather than a sales script.

Request a proposal
Last updated: July 2026. Regulatory forms, portals, and timelines change; specifics are re-verified periodically.

Entering the Saudi market?

Tell us about your product and timeline, and we will come back with a scoped proposal for the dossier and strategy work.

Request a proposal